Výsledky vyhledávání - Maximiliano Van Kooten
- Zobrazuji výsledky 1 - 4 z 4
-
1
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer Autor José Rodrigues-Pereira, Joo-Hang Kim, Manuel Magallanes, Dae Ho Lee, Jie Wang, Vinod Ganju, Luis Manuel Martínez-Barrera, Helen Barraclough, Maximiliano Van Kooten, Mauro Orlando
Vydáno 2011Artigo -
2
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Autor Frances A. Shepherd, José Rodrigues Pereira, Tudor‐Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour
Vydáno 2005Artigo -
3
LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or p... Autor Toni K. Choueiri, Tom Powles, Laurence Albigès, M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, Marco Maruzzo, Alberto Suárez Zaizar, Luis Fein, Fabio A. Schutz, Daniel Yick Chin Heng, F. Wang, Fabio Mataveli, Yih‐Leong Chang, Maximiliano van Kooten Losio, C. Suárez Rodríguez, Robert J. Motzer
Vydáno 2022Artigo -
4
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma Autor Toni K. Choueiri, Thomas Powles, Laurence Albigès, Mauricio Burotto, Cezary Szczylik, Bogdan Żurawski, Eduardo Yañez Ruiz, Marco Maruzzo, Alberto Suárez Zaizar, Luis Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Cristina Suárez, Robert J. Motzer
Vydáno 2023Artigo
Vyhledávací nástroje:
Související témata
Internal medicine
Medicine
Oncology
Cancer
Chemotherapy
Alternative medicine
Cabozantinib
Confidence interval
Environmental health
Gastroenterology
Hazard ratio
Immunotherapy
Ipilimumab
Lung cancer
Nivolumab
Pathology
Placebo
Population
Randomized controlled trial
Renal cell carcinoma
Surgery
Axitinib
Carboplatin
Cisplatin
Clinical endpoint
Clinical trial
Docetaxel
Epidermal growth factor receptor
Erlotinib
Erlotinib Hydrochloride